Orphazyme CEO stays silent in run-up to creditor meeting

Anders Vadsholt, CFO and acting CEO of Orphazyme, doesn’t want to speak about any recent or past events that led to the ongoing in-court restructuring process while it takes place, he informs MedWatch in a text message.
Anders Vadsholt, CFO and acting CEO of Orphazyme | Photo: Orphazyme / PR
Anders Vadsholt, CFO and acting CEO of Orphazyme | Photo: Orphazyme / PR
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

A line of defeats has been trailing biotech firm Orphazyme the past year, and the company recently announced that it is undergoing an in-court restructuring process.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading